Skip to main content
Top
Published in: BMC Psychiatry 1/2009

Open Access 01-12-2009 | Research article

Persistence and compliance to antidepressant treatment in patients with depression: A chart review

Authors: Norifusa Sawada, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Toshiaki Kikuchi, Takashi Handa, Haruo Kashima

Published in: BMC Psychiatry | Issue 1/2009

Login to get access

Abstract

Background

Adherence has recently been suggested to be divided into these two components: persistence (i.e., whether patients continue treatment or not) and compliance (i.e., whether patients take doses as instructed). However, no study has yet assessed these two clinically relevant components at the same time in adherence to antidepressant treatment in the clinical outpatient setting.

Methods

In this retrospective chart-review, 6-month adherence to antidepressants was examined in 367 outpatients with a major depressive disorder (ICD-10) (170 males; mean ± SD age 37.6 ± 13.9 years), who started antidepressant treatment from April 2006 through March 2007. Additionally, we evaluated Medication Possession Rate (MPR), defined as the total days a medication was dispensed to patients divided by the treatment period.

Results

Only 161 patients (44.3%) continued antidepressant treatment for 6 months. Among 252 patients who discontinued their initial antidepressant, 63.1% of these patients did so without consulting their physicians. Sertraline use was associated with a higher persistence rate at month 6 (odds ratio 2.59 in comparison with sulpiride), and the use of anxiolytic benzodiazepines had a positive effect on persistence to antidepressant treatment only at month 1 (odds ratio 2.14). An overall MPR was 0.77; 55.6% of patients were considered compliant (i.e., a MPR of ≥ 0.8).

Conclusion

Given a high rate of antidepressant discontinuation without consulting their physicians, closer communication between patients and their physicians should be encouraged. Although the use of anxiolytic benzodiazepines was associated with a higher persistence to antidepressant treatment at month 1, the use of these drugs should be avoided as a rule, given their well-known serious adverse effects.
Literature
1.
go back to reference Akincigil A, Bowblis JR, Levin C, Walkup JT, Jan S, Crystal S: Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care. 2007, 45 (4): 363-369. 10.1097/01.mlr.0000254574.23418.f6.CrossRefPubMedPubMedCentral Akincigil A, Bowblis JR, Levin C, Walkup JT, Jan S, Crystal S: Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care. 2007, 45 (4): 363-369. 10.1097/01.mlr.0000254574.23418.f6.CrossRefPubMedPubMedCentral
2.
go back to reference Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC: Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006, 44 (4): 300-303. 10.1097/01.mlr.0000204287.82701.9b.CrossRefPubMed Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC: Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006, 44 (4): 300-303. 10.1097/01.mlr.0000204287.82701.9b.CrossRefPubMed
3.
go back to reference Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET: Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry. 2005, 66 (2): 220-227.CrossRefPubMed Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET: Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry. 2005, 66 (2): 220-227.CrossRefPubMed
4.
go back to reference Hunot VM, Horne R, Leese MN, Churchill RC: A Cohort Study of Adherence to Antidepressants in Primary Care: The Influence of Antidepressant Concerns and Treatment Preferences. Prim Care Companion J Clin Psychiatry. 2007, 9 (2): 91-99.CrossRefPubMedPubMedCentral Hunot VM, Horne R, Leese MN, Churchill RC: A Cohort Study of Adherence to Antidepressants in Primary Care: The Influence of Antidepressant Concerns and Treatment Preferences. Prim Care Companion J Clin Psychiatry. 2007, 9 (2): 91-99.CrossRefPubMedPubMedCentral
5.
go back to reference Cooper D, Moisan J, Gregoire JP: Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007, 68 (6): 818-825.CrossRefPubMed Cooper D, Moisan J, Gregoire JP: Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007, 68 (6): 818-825.CrossRefPubMed
6.
go back to reference Cooke CE, Fatodu H: Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. J Manag Care Pharm. 2006, 12 (8): 649-655.PubMed Cooke CE, Fatodu H: Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. J Manag Care Pharm. 2006, 12 (8): 649-655.PubMed
7.
go back to reference Lachaine J, Petrella RJ, Merikle E, Ali F: Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Can J Cardiol. 2008, 24 (4): 269-273.CrossRefPubMedPubMedCentral Lachaine J, Petrella RJ, Merikle E, Ali F: Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Can J Cardiol. 2008, 24 (4): 269-273.CrossRefPubMedPubMedCentral
8.
go back to reference Hassan M, Madhavan SS, Kalsekar ID, Makela EH, Rajagopalan K, Islam S, Kavookjian J, Miller LA: Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother. 2007, 41 (11): 1812-1818. 10.1345/aph.1K205.CrossRefPubMed Hassan M, Madhavan SS, Kalsekar ID, Makela EH, Rajagopalan K, Islam S, Kavookjian J, Miller LA: Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother. 2007, 41 (11): 1812-1818. 10.1345/aph.1K205.CrossRefPubMed
9.
go back to reference Demyttenaere K, Adelin A, Patrick M, Walthere D, Katrien de B, Michele S: Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2008, 23 (1): 36-42. 10.1097/YIC.0b013e3282f1c1d8.CrossRefPubMed Demyttenaere K, Adelin A, Patrick M, Walthere D, Katrien de B, Michele S: Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2008, 23 (1): 36-42. 10.1097/YIC.0b013e3282f1c1d8.CrossRefPubMed
10.
go back to reference Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry. 2002, 159 (3): 469-473. 10.1176/appi.ajp.159.3.469.CrossRefPubMed Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry. 2002, 159 (3): 469-473. 10.1176/appi.ajp.159.3.469.CrossRefPubMed
11.
go back to reference Burra TA, Chen E, McIntyre RS, Grace SL, Blackmore ER, Stewart DE: Predictors of self-reported antidepressant adherence. Behav Med. 2007, 32 (4): 127-134. 10.3200/BMED.32.4.127-134.CrossRefPubMed Burra TA, Chen E, McIntyre RS, Grace SL, Blackmore ER, Stewart DE: Predictors of self-reported antidepressant adherence. Behav Med. 2007, 32 (4): 127-134. 10.3200/BMED.32.4.127-134.CrossRefPubMed
12.
go back to reference Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA: Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol. 2007, 27 (5): 451-458. 10.1097/jcp.0b013e31815152a5.CrossRefPubMed Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA: Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol. 2007, 27 (5): 451-458. 10.1097/jcp.0b013e31815152a5.CrossRefPubMed
13.
go back to reference Demyttenaere K, Van Ganse E, Gregoire J, Gaens E, Mesters P: Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol. 1998, 13 (1): 11-17. 10.1097/00004850-199801000-00002.CrossRefPubMed Demyttenaere K, Van Ganse E, Gregoire J, Gaens E, Mesters P: Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol. 1998, 13 (1): 11-17. 10.1097/00004850-199801000-00002.CrossRefPubMed
14.
go back to reference Inagaki A, Inada T, Fujii Y: Dose equivalents of psychotropic drugs.(in Japanese). 1999, Tokyo: Seiwa Press Inagaki A, Inada T, Fujii Y: Dose equivalents of psychotropic drugs.(in Japanese). 1999, Tokyo: Seiwa Press
15.
go back to reference Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tsunoda K, Takeuchi H, Kikuchi T, Nakajima S, Nomura K, Tomita M, et al: Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry Clin Neurosci. 2009, 63 (2): 244-246. 10.1111/j.1440-1819.2008.01920.x.CrossRefPubMed Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tsunoda K, Takeuchi H, Kikuchi T, Nakajima S, Nomura K, Tomita M, et al: Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry Clin Neurosci. 2009, 63 (2): 244-246. 10.1111/j.1440-1819.2008.01920.x.CrossRefPubMed
16.
go back to reference Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N: Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J. 2008, 10 (3): 207-213.PubMed Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N: Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J. 2008, 10 (3): 207-213.PubMed
17.
go back to reference Mackay FJ, Dunn NR, Wilton LV, Pearce GL, Freemantle SN, Mann RD: A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf. 1997, 6 (4): 235-246. 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3.CrossRefPubMed Mackay FJ, Dunn NR, Wilton LV, Pearce GL, Freemantle SN, Mann RD: A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf. 1997, 6 (4): 235-246. 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3.CrossRefPubMed
18.
go back to reference Mullins CD, Shaya FT, Meng F, Wang J, Harrison D: Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005, 25 (5): 660-667. 10.1592/phco.25.5.660.63590.CrossRefPubMed Mullins CD, Shaya FT, Meng F, Wang J, Harrison D: Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005, 25 (5): 660-667. 10.1592/phco.25.5.660.63590.CrossRefPubMed
19.
go back to reference Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000, 157 (4 Suppl): 1-45. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000, 157 (4 Suppl): 1-45.
20.
go back to reference Montgomery SA: Long-term treatment of depression. Br J Psychiatry Suppl. 1994, 31-36. 26 Montgomery SA: Long-term treatment of depression. Br J Psychiatry Suppl. 1994, 31-36. 26
21.
go back to reference Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC: Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 2008, 71 (20): 1572-1578. 10.1212/01.wnl.0000319693.10338.b9.CrossRefPubMed Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC: Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 2008, 71 (20): 1572-1578. 10.1212/01.wnl.0000319693.10338.b9.CrossRefPubMed
22.
go back to reference Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B: Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002, 288 (11): 1403-1409. 10.1001/jama.288.11.1403.CrossRefPubMed Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B: Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002, 288 (11): 1403-1409. 10.1001/jama.288.11.1403.CrossRefPubMed
23.
go back to reference Elwyn G, Edwards A, Wensing M, Hood K, Atwell C, Grol R: Shared decision making: developing the OPTION scale for measuring patient involvement. Qual Saf Health Care. 2003, 12 (2): 93-99. 10.1136/qhc.12.2.93.CrossRefPubMedPubMedCentral Elwyn G, Edwards A, Wensing M, Hood K, Atwell C, Grol R: Shared decision making: developing the OPTION scale for measuring patient involvement. Qual Saf Health Care. 2003, 12 (2): 93-99. 10.1136/qhc.12.2.93.CrossRefPubMedPubMedCentral
24.
go back to reference Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW: Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002, 36 (4): 578-584. 10.1345/aph.1A254.CrossRefPubMed Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW: Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002, 36 (4): 578-584. 10.1345/aph.1A254.CrossRefPubMed
25.
go back to reference Furukawa TA, Streiner DL, Young LT: Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord. 2001, 65 (2): 173-177. 10.1016/S0165-0327(00)00254-8.CrossRefPubMed Furukawa TA, Streiner DL, Young LT: Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord. 2001, 65 (2): 173-177. 10.1016/S0165-0327(00)00254-8.CrossRefPubMed
26.
go back to reference Angus WR, Romney DM: The effect of diazepam on patients' memory. J Clin Psychopharmacol. 1984, 4 (4): 203-206. 10.1097/00004714-198408000-00006.CrossRefPubMed Angus WR, Romney DM: The effect of diazepam on patients' memory. J Clin Psychopharmacol. 1984, 4 (4): 203-206. 10.1097/00004714-198408000-00006.CrossRefPubMed
27.
go back to reference Swift CG, Swift MR, Hamley J, Stevenson IH, Crooks J: Side-effect 'tolerance' in elderly long-term recipients of benzodiazepine hypnotics. Age Ageing. 1984, 13 (6): 335-343. 10.1093/ageing/13.6.335.CrossRefPubMed Swift CG, Swift MR, Hamley J, Stevenson IH, Crooks J: Side-effect 'tolerance' in elderly long-term recipients of benzodiazepine hypnotics. Age Ageing. 1984, 13 (6): 335-343. 10.1093/ageing/13.6.335.CrossRefPubMed
28.
go back to reference Nurmi-Luthje I, Kaukonen JP, Luthje P, Naboulsi H, Tanninen S, Kataja M, Kallio ML, Leppilampi M: Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: Comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging. 2006, 23 (1): 27-37. 10.2165/00002512-200623010-00003.CrossRefPubMed Nurmi-Luthje I, Kaukonen JP, Luthje P, Naboulsi H, Tanninen S, Kataja M, Kallio ML, Leppilampi M: Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: Comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging. 2006, 23 (1): 27-37. 10.2165/00002512-200623010-00003.CrossRefPubMed
29.
go back to reference Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006, 355 (15): 1525-1538. 10.1056/NEJMoa061240.CrossRefPubMed Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006, 355 (15): 1525-1538. 10.1056/NEJMoa061240.CrossRefPubMed
30.
go back to reference Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006, 163 (4): 611-622. 10.1176/appi.ajp.163.4.611.CrossRefPubMed Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006, 163 (4): 611-622. 10.1176/appi.ajp.163.4.611.CrossRefPubMed
31.
go back to reference Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC: Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol. 2000, 20 (6): 645-652. 10.1097/00004714-200012000-00010.CrossRefPubMed Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC: Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol. 2000, 20 (6): 645-652. 10.1097/00004714-200012000-00010.CrossRefPubMed
32.
go back to reference Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M: Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 2008, 16 (7): 584-593. 10.1097/JGP.0b013e318172b42d.CrossRefPubMed Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M: Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 2008, 16 (7): 584-593. 10.1097/JGP.0b013e318172b42d.CrossRefPubMed
33.
go back to reference Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003, 361 (9358): 653-661. 10.1016/S0140-6736(03)12599-8.CrossRefPubMed Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003, 361 (9358): 653-661. 10.1016/S0140-6736(03)12599-8.CrossRefPubMed
Metadata
Title
Persistence and compliance to antidepressant treatment in patients with depression: A chart review
Authors
Norifusa Sawada
Hiroyuki Uchida
Takefumi Suzuki
Koichiro Watanabe
Toshiaki Kikuchi
Takashi Handa
Haruo Kashima
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2009
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-9-38

Other articles of this Issue 1/2009

BMC Psychiatry 1/2009 Go to the issue